Elbasvir and grazoprevir and Nifedical XL
Determining the interaction of Elbasvir and grazoprevir and Nifedical XL and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:NIFEdipine may increase the blood levels of grazoprevir in some patients. This may increase the risk of side effects such as nausea, vomiting, and liver problems. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek prompt medical attention during treatment with grazoprevir if you develop signs and symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme. In 8 study subjects, administration of a single 100 mg dose of grazoprevir with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once daily) increased grazoprevir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) by 13%, 200% and 100%, respectively, compared to administration of grazoprevir alone. High plasma levels of grazoprevir may increase the risk of adverse effects such as alanine aminotransferase (ALT) elevations. Ketoconazole also increased the Cmax, AUC and Cmin of a single 50 mg dose of elbasvir by 29%, 80% and 89%, respectively. The extent to which other, less potent inhibitors of CYP450 3A4 may interact with elbasvir and grazoprevir is unknown.
MANAGEMENT: Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.
- "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Company Inc, Whitehouse Station, NJ.
Generic Name: elbasvir / grazoprevir
Brand name: Zepatier
Synonyms: Elbasvir and Grazoprevir
Generic Name: nifedipine
Brand name: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL, Adalat
Synonyms: Nifedical XL (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Elbasvir and grazoprevir-Nifedipine
- Elbasvir and grazoprevir-Nifedipine Capsules
- Elbasvir and grazoprevir-Nifedipine Extended-Release Tablets
- Elbasvir and grazoprevir-Niferex
- Elbasvir and grazoprevir-Niferex Elixir
- Elbasvir and grazoprevir-Night Cast R Topical
- Nifedical XL-Eldepryl
- Nifedical XL-Eldepryl Capsules
- Nifedical XL-Eldepryl Oral
- Nifedical XL-Eldepryl Tablets
- Nifedical XL-ELenzaPatch
- Nifedical XL-Elepsia XR